ArticleJournal of the Endocrine Society2025
Lean Body Mass as a Predictor of Levothyroxine Requirement in Primary Hypothyroidism as Compared to Actual Body Weight.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- [Clinical determinants of levothyroxine dosage adjusted for various body weights].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Association Between the Levothyroxine Therapy and the Levels of Anti-Thyroid Antibodies in Women with Hypothyroidism Due to Hashimoto's Thyroiditis-Narrative Review.International journal of molecular sciences · 2026Review
- Thyroid Hormone Replacement Dose Is Not Associated with Anti-TPO and Anti-TG Antibody Titers in Hashimoto's Disease.Journal of clinical medicine · 2026Article
- Lean Body Mass as a Predictor of Levothyroxine Requirement in Primary Hypothyroidism as Compared to Actual Body Weight.Journal of the Endocrine Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Levothyroxine (LT4) therapy for hypothyroidism is traditionally dosed at 1.6 μg/kg of actual body weight (ABW). However, ABW-based dosing often fails to proportionally adjust for increasing body weight. Ideal body weight (IBW) and lean body mass (LBM) have been proposed as alternatives, but data on these parameters on the larger hypothyroid population are lacking, particularly in Hashimoto thyroiditis. Objective: This study evaluates LBM- and IBW-based LT4 dosing and examines variability in ABW-based dosing across age, body mass index (BMI), and menopausal status. Methods: This cross-sectional study analyzed 720 patients with primary hypothyroidism on stable LT4 doses and in a euthyroid state for ≥6 months. ABW, BMI, LT4 dose, and thyrotropin (TSH) were recorded. IBW and LBM were calculated using Devine's and Boer's formulas, respectively. LT4 doses per ABW, IBW, and LBM were compared across age, BMI, and menopause. Results: Daily LT4 dose per kilogram of ABW decreased across BMI categories (18.5-24.9 kg/m Conclusion: LT4 dosing based on LBM offers a more consistent approach for managing hypothyroidism. A dose of 2.3 mcg/kg LBM may optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.